Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance

PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 8, 2021

Primary Completion Date

April 30, 2026

Study Completion Date

June 30, 2026

Conditions
Monoclonal Gammopathy
Interventions
DRUG

Isatuximab

"Isatuximab in IV form (10mg/kg q weekly x 4 doses followed by 10mg/kg q 2 weeks) for a total of 6 month duration. Doses should be initiated at 175 mg/hour up to a maximum of 400 mg/hour.~Isatuximab (SAR) is monoclonal antibody (mAb)."

Trial Locations (2)

10032

RECRUITING

Columbia University Irving Medical Center, New York

02114

RECRUITING

Massachusetts General Hospital, Renal Associates Clinic, Boston

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Columbia University

OTHER